The receptor tyrosine kinase EGFR binds the growth factor ligand EGF.
The EGFR-EGF complex binds another EGFR-EGF complex.
The EGFR-EGFR complex binds GRB2.
EGFR-bound GRB2 binds SOS1.
GRB2-bound SOS1 binds NRAS that is not bound to BRAF.
SOS1-bound NRAS binds GTP.
GTP-bound NRAS that is not bound to SOS1 binds BRAF.
Vemurafenib binds BRAF.
BRAF V600E that is not bound to Vemurafenib phosphorylates MAP2K1.
PP2A-alpha dephosphorylates MAP2K1 that is not bound to ERK2.
Phosphorylated MAP2K1 is activated.
Active MAP2K1 that is not bound to PP2A-alpha phosphorylates ERK2.
DUSP6 dephosphorylates ERK2.
MAP2K1 ubiquitinates MAPK1.
MAP2K1 ribosylates MAPK1.
MAP2K1 hydroxylates MAPK1.
MAP2K1 acetylates MAPK1.
MAP2K1 farnesylates MAPK1.
MAP2K1 deubiquitinates MAPK1.
MAP2K1 deribosylates MAPK1.
MAP2K1 dehydroxylates MAPK1.
MAP2K1 deacetylates MAPK1.
MAP2K1 defarnesylates MAPK1.
Ubiquitinated MAPK1 is degraded.
MAPK1 is synthesized.
MAP2K1 transcribes MAPK1.
MAP2K1 synthesizes MAPK1.
MAP2K1 degrades MAPK1.
MAPK1 translocates to the nucleus.
MAPK1 translocates from the nucleus.
MAPK1 translocates from the plasma membrane to the nucleus.
EGF leads to the activation of MAPK1.
Stimulation by EGF activates MAPK1.
Vemurafenib leads to the deactivation of MAPK1.
EGFR autophosphorylates itself.
EGFR autophosphorylates itself on Y1234.
EGFR bound to EGFR transphosphorylates itself.
